Shares of CVS Health Corp (NYSE:CVS) ended Monday session in red amid volatile trading. The shares closed down -0.95 points or -1.05% at $89.17 with 1.07 billion shares getting traded. Post opening the session at $90.13, the shares hit an intraday low of $89.00 and an intraday high of $90.23 and the price vacillated in this range throughout the day. The company has a market cap of $95.04 billion and the numbers of outstanding shares have been calculated to be 1.07 billion shares.
CVS Health Corp (CVS) on Sept. 19, 2016 announced it will expand its commitment to preventing drug abuse among young people through investments in two prevention education programs. The CVS Health Foundation will launch a new partnership with DoSomething.org to create a peer-to-peer prevention and intervention program delivered to young people via text message and online. CVS Health is also renewing its successful Pharmacists Teach program, which connects CVS pharmacists to local high school students in their communities to discuss the dangers of prescription drug abuse. Entering its second year, the program has already reached more than 100,000 students across the country.
“As a pharmacy innovation company, we care deeply about preventing drug abuse among young people and we are proud of these unique programs that will make a meaningful difference for so many teens and their families,” said Helena Foulkes, President, CVS Pharmacy. “We have seen tremendous enthusiasm from our CVS pharmacists, who have volunteered to speak to more than 100,000 students about the dangers of prescription drug abuse as part of our Pharmacists Teach program, which will continue into this new school year. And, we are pleased to expand on our abuse prevention efforts with a new program to reach young people digitally through our partnership with DoSomething.org.”
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) ended Monday session in green amid volatile trading. The shares closed up +0.19 points or 0.24 at $78.99 with 1.32 billion shares getting traded. Post opening the session at $78.92, the shares hit an intraday low of $78.81 and an intraday high of $79.51 and the price vacillated in this range throughout the day. The company has a market cap of $104.19 billion and the numbers of outstanding shares have been calculated to be 1.32 billion shares.
Gilead Sciences, Inc. (GILD) on September 16, 2016 announced the pricing of senior unsecured notes in an aggregate principal amount of $5 billion, in an underwritten, registered public offering, consisting of five tranches:
$500 million of 1.950% senior notes maturing in 2022
$750 million of 2.500% senior notes maturing in 2023
$1,250 million of 2.950% senior notes maturing in 2027
$750 million of 4.000% senior notes maturing in 2036
$1,750 million of 4.150% senior notes maturing in 2047
The senior notes are rated A by Standard & Poor’s and A3 by Moody’s. The offering is expected to close September 20, 2016, subject to customary closing conditions.
Gilead intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of debt, working capital, payment of dividends, the repurchase of its outstanding common stock pursuant to its authorized share repurchase program and future acquisitions.